Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2rrCLL 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma, Mantle-Cell 1Leukemia, B-Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Rituximab 130Cyclophosphamide 41Bendamustine Hydrochloride 39venetoclax 25fludarabine 25obinutuzumab 24Lenalidomide 23ibrutinib 22Gemcitabine 22Vincristine 20Prednisone 20tositumomab I-131 19Doxorubicin 19plerixafor 14Dexamethasone 14Granulocyte Colony-Stimulating Factor 12pirtobrutinib 11Brentuximab Vedotin 11glofitamab 10tocilizumab 9pembrolizumab 9ibritumomab tiuxetan 9Etoposide 9Azacitidine 9polatuzumab vedotin 8parsaclisib 8copanlisib 8acalabrutinib 8Drug Therapy 8ublituximab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Non-Hodgkin × dinaciclib × Clear all
NCT00871910 2017-10-23

Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)

Merck Sharp & Dohme LLC

Phase 1 Completed
81 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT00871663 2015-04-20

Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)

Merck Sharp & Dohme LLC

Phase 1 Completed
123 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡